Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... class of ultraviolet photodiode could help meet the U.S. ... to detect anthrax and other bioterrorism agents in the ... which are bulky, fragile and require a lot of ... a complex filter so that they only detect the ...
... VANCOUVER, BC, Aug. 8 /PRNewswire-FirstCall/ - Chromos ... today that the Supreme,Court of British Columbia ... Order"),dated August 8, 2008 in connection with ... "Arrangement") involving, among others, the,Company, Calyx Bio-Ventures ...
... 8 Inverness Medical,Innovations, Inc. (Amex: IMA ... health management solutions, is featuring its,new TB diagnostic ... AIDS,conference (AIDS 2008)., The test, which was ... a much needed aid in the diagnosis of ...
Cached Biology Technology:Avalanche photodiodes target bioterrorism agents 2Avalanche photodiodes target bioterrorism agents 3Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 2Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 3Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008 2
(Date:9/30/2014)... September 30, 2014--Sea monkeys have captured the popular attention ... easily observable life cycle -- sold as dehydrated eggs, ... given little more than a tank of salt water. ... pattern: Like other zooplankton, brine shrimp vertically migrate in ... closer to the surface at night and retreating deeper ...
(Date:9/30/2014)... and engineers, led by Clemson University associate professor ... grant from the U.S. Department of Energy,s Experimental ... direct positive impact on South Carolina in the ... contaminants. , "Understanding the scientific and engineering needs ... of nuclear technologies is imperative if South Carolina ...
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Shape up quickly -- applies to fish, too! 2
... A new study reconstructing thousands of years of ... prescribed fire, or controlled burns, as a tool to reduce ... protect rare ecological communities in the region,s forests. ... samples dating from 1977 to more than 4,000 years ago ...
... 2010 -- Spectacularly increased yields and improved taste have ... the Robert H. Smith Faculty of Agriculture, Food and ... Harbor Laboratory (CSHL), New York. The researchers have ... controls when plants make flowers and that works in ...
... to measure blood flow in the lungs of people who ... most at risk of emphysema before the disease damages and ... of Iowa study. The study found that smokers who ... lung function, have very different blood flow patterns in their ...
Cached Biology News:4,000-year study supports use of prescribed burns in Southern Appalachians 24,000-year study supports use of prescribed burns in Southern Appalachians 3Genetic key discovered to dramatically increase yields and improve taste of hybrid tomato plants 2Genetic key discovered to dramatically increase yields and improve taste of hybrid tomato plants 3New test could identify smokers at risk of emphysema 2
...
...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
... The GeneSwitch Cell Lines stably ... pSwitch. Each cell line is functionally ... transfection with the expression control vector ... expression after treatment with mifepristone (Figure ...
Biology Products: